Shareholder Alert: The Ademi Firm Continues to Investigate Whether CARGO Therapeutics, Inc. is Obtaining a Fair Price for its Public Shareholders
Cargo TherapeuticsCargo Therapeutics(US:CRGX) Businesswire·2025-09-15 05:40

Core Viewpoint - The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for potential breaches of fiduciary duty and other legal violations related to its transaction with Concentra Biosciences [1]. Group 1 - In the transaction, shareholders of CARGO will receive $4.379 in cash per share [1]. - Additionally, shareholders will receive one non-transferable contingent value right [1].